NATERA INC (Common Stock) – ticker 45E (NTRA)
Natera, Inc. (NTRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Natera, Inc. (NTRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NTRA & NVDA Partner to Improve AI Models for Precision Medicine
Natera teams up with NVIDIA to train multimodal AI models, aiming to improve precision care through faster, scalable analysis of complex medical data.
Natera, Inc. (NTRA) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Natera, Inc. ( NTRA ) 7th Annual Wolfe Research Healthcare Conference November 19, 2025 10:00 AM EST Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC All right. So last run of the day.
Natera, Inc. (NTRA) Presents at Jefferies London Healthcare Conference 2025 Transcript
Natera, Inc. ( NTRA ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM EST Company Participants Steve Chapman - CEO & Director Mike Brophy - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division So I am going to go ahead and kick it off. I'm Tycho Peterson from the Jefferies Life Science team.
Natera, Inc. (NTRA) Q3 2025 Earnings Call Transcript
Natera, Inc. ( NTRA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Solomon Moshkevich - President of Clinical Diagnostics Alexey Aleshin - GM of Oncology and ECD & Chief Medical Officer Conference Call Participants Noah Kava - Jefferies LLC, Research Division Douglas Schenkel - Wolfe Research, LLC Daniel Brennan - TD Cowen, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Puneet Souda - Leerink Partners LLC, Research Division Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Presentation Operator Welcome to Natera's 2025 Third Quarter Financial Results Conference Call.
Here's What Key Metrics Tell Us About Natera (NTRA) Q3 Earnings
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates
Natera (NTRA) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.26 per share a year ago.
Natera, Inc. (NTRA) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Natera, Inc. (NASDAQ:NTRA ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 10:30 AM EDT Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Eve Burstein - Sanford C. Bernstein & Co., LLC.
Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability
For my first rating of Natera, I called it a buy, while today's consensus seems to be between a hold and a strong buy. Both proven revenue growth and expected future growth outlooks are upside drivers, including positive cashflow, despite reported net losses. The company plays a key role in providing specialized testing solutions in the cancer-care and kidney-care space, among others.
Natera Shares Rise on the Launch of AI Platform for Precision Oncology
NTRA shares gain after unveiling its in-house AI platform, built on vast oncology datasets to transform precision cancer care.
Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript
Natera, Inc. (NASDAQ:NTRA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Alexey Aleshin - GM of Oncology and ECD & Chief Medical Officer Michael B. Brophy - Chief Financial Officer Solomon Moshkevich - President of Clinical Diagnostics Steven Leonard Chapman - CEO & Director Conference Call Participants Catherine Walden Ramsey Schulte - Robert W.
Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Natera (NTRA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
